2230 Stock Overview
Saudi Chemical Holding Company engages in the explosives, medicines and medical supplies, and production of ammonium nitrate businesses in the Kingdom of Saudi Arabia and internationally.
Saudi Chemical Holding Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||ر.س30.20|
|52 Week High||ر.س43.25|
|52 Week Low||ر.س27.00|
|1 Month Change||-8.49%|
|3 Month Change||-12.84%|
|1 Year Change||-25.98%|
|3 Year Change||29.06%|
|5 Year Change||4.70%|
|Change since IPO||51.71%|
Recent News & Updates
|2230||SA Healthcare||SA Market|
Return vs Industry: 2230 underperformed the SA Healthcare industry which returned 19.2% over the past year.
Return vs Market: 2230 underperformed the SA Market which returned 12.7% over the past year.
|2230 Average Weekly Movement||4.6%|
|Healthcare Industry Average Movement||4.9%|
|Market Average Movement||4.8%|
|10% most volatile stocks in SA Market||7.0%|
|10% least volatile stocks in SA Market||3.1%|
Stable Share Price: 2230 is not significantly more volatile than the rest of SA stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 2230's weekly volatility (5%) has been stable over the past year.
About the Company
Saudi Chemical Holding Company engages in the explosives, medicines and medical supplies, and production of ammonium nitrate businesses in the Kingdom of Saudi Arabia and internationally. The company manufactures and sells explosives and their derivatives for civil and military uses, as well as provides technical support services for explosions. It also engages in the manufacturing, wholesale, and retail trading of medicines, medical materials and syrups, pharmaceutical preparations, medical and surgical tools and equipment, supplies of hospitals and medical centers, and its related spare parts and food items; and manufacturing of ammonium nitrate.
Saudi Chemical Holding Fundamentals Summary
|2230 fundamental statistics|
Is 2230 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2230 income statement (TTM)|
|Cost of Revenue||ر.س2.92b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.73|
|Net Profit Margin||1.84%|
How did 2230 perform over the long term?See historical performance and comparison
1.7%Current Dividend Yield
Is 2230 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2230?
Other financial metrics that can be useful for relative valuation.
|What is 2230's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 2230's PE Ratio compare to its peers?
|2230 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
9530 Arabian International Healthcare Holding
4005 National Medical Care
4009 Middle East Healthcare
2140 Ayyan Investment
2230 Saudi Chemical Holding
Price-To-Earnings vs Peers: 2230 is good value based on its Price-To-Earnings Ratio (41.4x) compared to the peer average (70.1x).
Price to Earnings Ratio vs Industry
How does 2230's PE Ratio compare vs other companies in the Asian Healthcare Industry?
Price-To-Earnings vs Industry: 2230 is expensive based on its Price-To-Earnings Ratio (41.4x) compared to the SA Healthcare industry average (37.9x)
Price to Earnings Ratio vs Fair Ratio
What is 2230's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||41.4x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 2230's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 2230 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2230 (SAR30.2) is trading above our estimate of fair value (SAR4.22)
Significantly Below Fair Value: 2230 is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2230's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Saudi Chemical Holding forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Saudi Chemical Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of 2230’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
How has Saudi Chemical Holding performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2230 has high quality earnings.
Growing Profit Margin: 2230's current net profit margins (1.8%) are lower than last year (2.2%).
Past Earnings Growth Analysis
Earnings Trend: 2230's earnings have declined by 22.1% per year over the past 5 years.
Accelerating Growth: 2230's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2230 had negative earnings growth (-20.1%) over the past year, making it difficult to compare to the Healthcare industry average (2.4%).
Return on Equity
High ROE: 2230's Return on Equity (3.8%) is considered low.
Discover strong past performing companies
How is Saudi Chemical Holding's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 2230's short term assets (SAR3.1B) exceed its short term liabilities (SAR2.6B).
Long Term Liabilities: 2230's short term assets (SAR3.1B) exceed its long term liabilities (SAR419.5M).
Debt to Equity History and Analysis
Debt Level: 2230's net debt to equity ratio (119.1%) is considered high.
Reducing Debt: 2230's debt to equity ratio has increased from 56.9% to 126% over the past 5 years.
Debt Coverage: 2230's debt is not well covered by operating cash flow (9%).
Interest Coverage: 2230's interest payments on its debt are well covered by EBIT (3.3x coverage).
Discover healthy companies
What is Saudi Chemical Holding current dividend yield, its reliability and sustainability?
Dividend Score 1/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 2230's dividend (1.66%) isn’t notable compared to the bottom 25% of dividend payers in the SA market (1.95%).
High Dividend: 2230's dividend (1.66%) is low compared to the top 25% of dividend payers in the SA market (4.5%).
Stability and Growth of Payments
Stable Dividend: 2230's dividend payments have been volatile in the past 10 years.
Growing Dividend: 2230's dividend payments have fallen over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (68.4%), 2230's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (4868.4%), 2230's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Mr. Thamer Mohammed Al-Muhaid serves as Group Chief Executive Officer of Saudi Chemical Holding Company. Mr. Al-Muhaid served as Deputy General Manager of the Saudi Chemical Company Ltd., General Manager a...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Saudi Chemical Holding Company's employee growth, exchange listings and data sources
- Name: Saudi Chemical Holding Company
- Ticker: 2230
- Exchange: SASE
- Founded: 1972
- Industry: Health Care Distributors
- Sector: Healthcare
- Implied Market Cap: ر.س2.546b
- Shares outstanding: 84.32m
- Website: https://www.saudichemical.com
- Saudi Chemical Holding Company
- P.O. Box 2665
- Saudi Arabia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/27 00:00|
|End of Day Share Price||2022/06/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.